Published in Neuro Oncol on February 01, 2017
An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci Rep (2017) 0.75
Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care. Ophthalmology (2016) 0.75
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol (1988) 8.61
Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol (2007) 3.44
Plexiform neurofibromas. Am J Med Genet (1999) 2.97
CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology (1998) 2.32
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph (2004) 1.50
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology (2007) 1.47
Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol (2006) 1.42
Human interferons alpha, beta and omega. Growth Factors (2004) 1.30
Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology (2009) 1.14
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets (2009) 1.10
Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology (2011) 1.08
Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer (1996) 1.03
Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr (2011) 1.02
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer (2014) 1.01
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology (2003) 0.98
Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem (2004) 0.96
Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology (2013) 0.92
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer (2014) 0.90
Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas. Pediatrics (2014) 0.89
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol (2014) 0.89
5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother (2012) 0.88